These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23548649)

  • 1. Systematic review and quality assessment of cost-effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer.
    Leung HW; Chan AL; Leung MS; Lu CL
    Ann Pharmacother; 2013 Apr; 47(4):506-18. PubMed ID: 23548649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
    Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
    Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
    Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of fecal DNA screening for colorectal cancer: a systematic review and quality appraisal of the literature.
    Skally M; Hanly P; Sharp L
    Appl Health Econ Health Policy; 2013 Jun; 11(3):181-92. PubMed ID: 23549792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
    Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
    Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
    Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
    Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
    Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
    J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.
    Chan AL; Leung HW; Lu CL; Lin SJ
    Ann Pharmacother; 2009 Feb; 43(2):296-303. PubMed ID: 19193576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analyses of drug therapies in breast cancer: a systematic review.
    Nerich V; Saing S; Gamper EM; Kemmler G; Daval F; Pivot X; Holzner B
    Breast Cancer Res Treat; 2016 Oct; 159(3):407-24. PubMed ID: 27572551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and quality assessment of economic evaluation studies of injury prevention.
    Polinder S; Segui-Gomez M; Toet H; Belt E; Sethi D; Racioppi F; van Beeck EF
    Accid Anal Prev; 2012 Mar; 45():211-21. PubMed ID: 22269503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer.
    Krol M; Koopman M; Uyl-de Groot C; Punt CJ
    Expert Opin Pharmacother; 2007 Jun; 8(9):1313-28. PubMed ID: 17563265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review.
    Degeling K; Vu M; Koffijberg H; Wong HL; Koopman M; Gibbs P; IJzerman M
    Pharmacoeconomics; 2020 Jul; 38(7):683-713. PubMed ID: 32319026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
    Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
    Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
    Aguiar PM; Lima TM; Storpirtis S
    J Clin Pharm Ther; 2016 Apr; 41(2):189-97. PubMed ID: 27009796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer.
    Seo MK; Cairns J
    PLoS One; 2018; 13(9):e0204496. PubMed ID: 30256829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
    Franken MD; van Rooijen EM; May AM; Koffijberg H; van Tinteren H; Mol L; Ten Tije AJ; Creemers GJ; van der Velden AMT; Tanis BC; Uyl-de Groot CA; Punt CJA; Koopman M; van Oijen MGH
    Eur J Cancer; 2017 Apr; 75():204-212. PubMed ID: 28237866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.